Commitments and Contingencies (Details)			1 Months Ended			9 Months Ended
	Apr. 13, 2020 USD ($)	Sep. 03, 2014 USD ($) shares	Nov. 30, 2020 USD ($)	Mar. 31, 2020 USD ($) $ / shares	Jan. 31, 2020 USD ($)	Sep. 30, 2020 USD ($) m²
Commitments and Contingencies (Details) [Line Items]
Commitments related to agreements						$ 450,000
Maximum payment for commitment milestones						$ 7,900,000
Percentage for royalties						6.00%
Office space (in Square Meters) | m²						6,200
Office rent amount						$ 11,883
Office rent amount, per square foot						23.00
Cash paid to acquire Hy Biopharma intangible asset		$ 275,000
Shares issued in connection with Hy BioPharma asset purchase agreement (in Shares) | shares		184,912
Fair value of shares issued in connection with Hy BioPharma asset purchase		$ 3,750,000		$ 1,956,182
Effective price per share (in Dollars per share) | $ / shares				$ 2.56
Asset purchase agreement total expense				$ 5,000,000
Additional Payments						$ 5,000,000
ownership of the Company outstanding						19.90%
CARES Act loan, description	the Company was advised that one of its principal banks, JPMorgan Chase Bank, N.A., had approved a $417,830 loan (the “Loan”) under the Paycheck Protection Program (“PPP”) pursuant to the Coronavirus Aid, Relief and Economic Security Act that was signed into law on March 27, 2020. As a U.S. small business, the Company qualified for the PPP, which allows businesses and nonprofits with fewer than 500 employees to obtain loans of up to $10 million to incentivize companies to maintain their workers as they manage the business disruptions caused by the COVID-19 pandemic. The PPP provides for loans for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The PPP loan proceeds may be used for eligible purposes, including payroll, benefits, rent and utilities.
Loan amount	$ 417,830
Short term portion loan amount						$ 255,341
Long term portion loan amount						162,489
Accrued interest expense						$ 1,706
Loan description						The Loan bears interest at a fixed rate of 0.98% per annum, with the first six months of interest and principal deferred. Some or all of the Loan may be forgiven if at least 75% of the Loan proceeds are used by the Company to cover payroll costs, including benefits and if the Company maintains its employment and compensation within certain parameters during the eight-week or twenty-four-week period following the Loan origination date and complies with other relevant conditions.
Legal proceedings description						the Company filed a demand for arbitration against Emergent BioSolutions, Inc. ("Emergent") and certain of its subsidiaries with the American Arbitration Association in Mercer County, New Jersey. The Company alleges in the arbitration various breaches of contracts and warranties as well as acts of fraud. Emergent has answered that demand for arbitration denying the allegations and asserting affirmative defenses. (see Part II, Item 1 – Legal Proceeding) The Company is seeking to recover damages in excess of $19 million from Emergent. While the Company intends to vigorously pursue this arbitration, the Company cannot offer any assurances that it will recover any damages from Emergent. The Company has received invoices from Emergent related to the above matter. No accrual has been made for these invoices as management deems them invalid because Emergent failed to perform under the applicable contracts, and not probable of being required to pay them based on the numerous breaches sited in the pending arbitration. These invoices total approximately $331,000.
Subsequent Event [Member]
Commitments and Contingencies (Details) [Line Items]
Office rent amount			$ 11,108
Office rent amount, per square foot			21.50
Minimum [Member]
Commitments and Contingencies (Details) [Line Items]
Authorized shares to be issued					$ 5,000
Maximum [Member]
Commitments and Contingencies (Details) [Line Items]
Authorized shares to be issued					$ 500,000